NICE Rejects Novartis’ Xolair Use In Younger Children
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE’s analysis found that omalizumab was only useful in reducing the rate of clinically significant exacerbations in children with asthma who were having three of more exacerbations per year.
You may also be interested in...
NICE Rejects Novartis’ Xolair In Harbinger Of Cost Reevaluation Process
Draft guidance from NICE concludes that Novartis’ asthma drug Xolair, which was previously viewed as cost-effective, is no longer worth the expense based on new independent economic modeling and mortality data. The re-evaluation process is spreading through Europe as governments move to restrain costs, and that may spell trouble for manufacturers.
UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities
The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.
UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities
The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.